KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Depreciation & Amortization: 2015-2025

Historic Accumulated Depreciation & Amortization for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $85.6 million.

  • CRISPR Therapeutics AG's Accumulated Depreciation & Amortization rose 26.29% to $85.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.5 million, marking a year-over-year increase of 30.47%. This contributed to the annual value of $72.3 million for FY2024, which is 35.26% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Accumulated Depreciation & Amortization stood at $85.6 million, which was up 4.92% from $81.6 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Accumulated Depreciation & Amortization high stood at $85.6 million for Q3 2025, and its period low was $23.9 million during Q1 2021.
  • For the 3-year period, CRISPR Therapeutics AG's Accumulated Depreciation & Amortization averaged around $62.7 million, with its median value being $63.1 million (2024).
  • Within the past 5 years, the most significant YoY rise in CRISPR Therapeutics AG's Accumulated Depreciation & Amortization was 85.67% (2022), while the steepest drop was 14.80% (2022).
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Accumulated Depreciation & Amortization stood at $37.8 million in 2021, then declined by 10.51% to $33.8 million in 2022, then spiked by 57.94% to $53.4 million in 2023, then spiked by 35.26% to $72.3 million in 2024, then increased by 26.29% to $85.6 million in 2025.
  • Its last three reported values are $85.6 million in Q3 2025, $81.6 million for Q2 2025, and $77.0 million during Q1 2025.